Eli Lilly: In The Eye Of The Drug Pricing Storm - Expect Volatility, And Buy (NYSE:LLY)

Eli Lilly's GLP-1 drugs fuel massive growth, with potential $60bn+ annual revenue. Check out why I remain bullish long term on LLY stock.